NEW YORK (GenomeWeb) – Roche plans to take a majority stake worth more than $1 billion in oncology genomic testing firm Foundation Medicine, and will invest potentially more than $150 million in R&D, the companies said today. In addition, Roche will help to expand sales of Foundation's tests outside the US.

Roche will commence a tender offer for approximately 15.6 million shares of Foundation Medicine at $50 per share, for an aggregate value of about $780 million. The offer price is a 109 percent premium over Foundation Medicine's closing price last Friday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.